PT-141, bremelanotide, is one of the few molecules in this catalogue with a drug approval behind it. It is a melanocortin receptor agonist. Sold here as research material, not as a medicine.
Bio-Peptide, 10 mg
105,00 złAdd to cartAvailable on backorder
Genheal, 10 mg
100,00 złAdd to cart3 in stock (can be backordered)
What is in the vial
Bio-Peptide and Genheal both supply 10 mg vials of lyophilised powder. Compare that with the approved medicine, which delivers 1.75 mg from an autoinjector, and the scale of one vial is easy to see. A 10 mg vial with 2 ml of bacteriostatic water gives 5 mg per millilitre; the arithmetic and the conversion into insulin syringe units are in the guides on reconstitution and syringe units.
The approved medicine
The United States Food and Drug Administration approved bremelanotide on 21 June 2019 as Vyleesi, for premenopausal women with acquired, generalised hypoactive sexual desire disorder causing marked distress, where it does not stem from another condition, medication or relationship problem. The product label states that the way the drug improves desire is not known.
In the registration trials the effect was moderate: an increase of 1.2 points or more on the desire score in roughly 25 percent of treated participants, against roughly 17 percent on placebo. The approved product is given from an autoinjector at least 45 minutes before planned activity, as needed rather than daily.
What you are not buying
Research material is not Vyleesi. The same molecule in the registered medicine comes with a known dose, pharmaceutical quality control and an autoinjector. Those three things are the difference, and pretending otherwise would be a claim we cannot support.
The narrow indication matters too. The approval covers one specific diagnosis in premenopausal women; it says nothing about anyone else, and the label itself does not claim to know the mechanism.
How it relates to melanotan II
Bremelanotide is a metabolite of melanotan II and acts on the same receptor family, which is why the two sit together in the libido and tanning group. The difference is the path each took: one was developed as a medicine and reviewed by a regulator, the other never was.
Status
Approved in the United States for the indication above, as a prescription medicine. The vial here is research material. We publish no dosing schedules; the label figures above describe the registered product and are not a recommendation.
Handling and verification
Supplied as lyophilised powder. Storage rules change once it is dissolved: see storage. Check the code under the hologram and the batch certificate as described in check your product. We ship within Poland and abroad; outside Poland the cost is quoted individually, depending on weight and destination country. Details: shipping and payments.
Questions
Is PT-141 an approved medicine?
The molecule is, as Vyleesi, approved in the United States in 2019 for one narrow indication in premenopausal women. The vial sold here is research material.
How well did it work in trials?
Moderately: an increase of 1.2 points or more on the desire score in roughly 25 percent of treated participants, against roughly 17 percent on placebo.
Is the mechanism known?
The product label states that the way the drug improves desire is not known.
Is it related to melanotan II?
Yes, it is a metabolite of it and acts on the same receptor family, but only bremelanotide went through a regulatory review.